***Please note new date***Biotechnology Analysts hold a conference call with CEO Gline and CFO Pulik on October 25 at 11 am hosted by JPMorgan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ROIV:
- Roivant (NASDAQ:ROIV) Gains after Roche’s $7.1 Billion Buy of Televant
- Roche to acquire Telavant from Roivant Sciences for $7.1B upfront
- Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
- Guggenheim starts ‘solid and diversified’ Roivant Sciences with a Buy
- Roivant Sciences initiated with a Buy at Guggenheim